 |
Antithrombin III (human) |
|---|---|
| Trade Name | Thrombate Iii |
| Orphan Indication | For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli |
| USA Market Approval | USA |
| USA Designation Date | 1984-11-26 00:00:00 |
| Sponsor | Bayer Corporation;Pharmaceutical Division, Biological Products, 400 Morgan Lane;New Haven, Connecticut, 06516 |
